Actimis Pharmaceuticals

About Actimis Pharmaceuticals

Actimis Pharmaceuticals was a biopharmaceutical firm with a clear focus on developing and bringing to market small molecule therapeutics. The company was established in November 2004 as a spin-off from Bayer Healthcare AG. Founded by Dr. Kevin B. Bacon, who also served as the Chief Scientific Officer, the company operated from San Diego, California. The leadership team also included Dr. Peter McWilliams as President and acting CEO.

The company's core business was the research and development of treatments for severe respiratory, inflammatory, and autoimmune diseases. Its therapeutic pipeline targeted conditions such as asthma, chronic obstructive pulmonary disease (COPD), inflammatory dermatoses, inflammatory bowel disease, and rheumatoid arthritis. Actimis' business model was centered on advancing its drug candidates through clinical trials to demonstrate value and attract acquisition or partnership from larger pharmaceutical corporations. This strategy was realized in June 2008 when Boehringer Ingelheim initiated an acquisition of Actimis. The deal was structured as a milestone-based buyout, potentially worth up to $515 million, contingent on the successful progression of Actimis's lead drug candidate.

The primary product in Actimis's portfolio was AP768, a compound aimed at treating asthma and allergic rhinitis. AP768 functions by interacting with CRTH2, a chemo-attractant receptor that is a target for these respiratory conditions. At the time of the acquisition announcement, AP768 was in Phase I clinical trials and had shown a more effective mechanism of action in animal models compared to existing leukotriene receptor antagonists. The acquisition by Boehringer Ingelheim was designed to bolster its own respiratory disease portfolio, which included the successful COPD treatment, Spiriva. The deal structure involved Boehringer acquiring all of Actimis's shares if AP768 successfully advanced to Phase III trials, a transaction that represented Boehringer's first significant foray into acquiring a biotech company.